# Natalizumab Treatment of Progressive Multiple Sclerosis

> **NCT01077466** · PHASE2 · COMPLETED · sponsor: **Rigshospitalet, Denmark** · enrollment: 24 (actual)

## Conditions studied

- Primary Progressive Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Natalizumab

## Key facts

- **NCT ID:** NCT01077466
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2012-02-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01077466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01077466, "Natalizumab Treatment of Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01077466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*